NYSE:PFE - Pfizer News Headlines

Sign in or create an account to add this stock to your watchlist.
$44.06 +0.31 (+0.71 %)
(As of 09/21/2018 04:00 PM ET)
Previous Close$43.75
Today's Range$43.61 - $44.19
52-Week Range$33.20 - $44.19
Volume35.19 million shs
Average Volume21.93 million shs
Market Capitalization$257.52 billion
P/E Ratio16.62
Dividend Yield3.14%
Beta0.96

Headlines

Pfizer (NYSE PFE) News Headlines

Source:
DateHeadline
Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy StatusPfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status
finance.yahoo.com - September 21 at 3:28 PM
Eli Lilly Prices Animal Health Unit IPO at $24 Per ShareEli Lilly Prices Animal Health Unit IPO at $24 Per Share
finance.yahoo.com - September 20 at 3:34 PM
Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?
www.zacks.com - September 20 at 11:06 AM
FDA grants Breakthrough Therapy designation to Pfizers PF-06482077FDA grants Breakthrough Therapy designation to Pfizer's PF-06482077
seekingalpha.com - September 20 at 11:06 AM
Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years ...Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years ...
www.businesswire.com - September 20 at 11:06 AM
Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 EstimatesPharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates
finance.yahoo.com - September 20 at 11:06 AM
Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and OlderPfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
finance.yahoo.com - September 20 at 11:06 AM
[$$] Companies Brexit Challenge: Preparing for the Unknown[$$] Companies' Brexit Challenge: Preparing for the Unknown
finance.yahoo.com - September 20 at 11:06 AM
Pharma Stocks: Pfizer’s Revenue Trend and 2018 EstimatesPharma Stocks: Pfizer’s Revenue Trend and 2018 Estimates
finance.yahoo.com - September 19 at 3:37 PM
Pfizer And Conatus: Emricasan And NASHPfizer And Conatus: Emricasan And NASH
seekingalpha.com - September 19 at 10:17 AM
Pfizer Inc. (PFE) Short Interest UpdatePfizer Inc. (PFE) Short Interest Update
www.americanbankingnews.com - September 19 at 1:38 AM
Health care ETF surges toward record in a broad sector rallyHealth care ETF surges toward record in a broad sector rally
finance.yahoo.com - September 18 at 3:42 PM
New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific MeetingNew Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting
finance.yahoo.com - September 18 at 3:42 PM
Pfizer Reports Addl Analyses From Tafamidis Phase 3 ATTR-ACT StudyPfizer Reports Addl Analyses From Tafamidis Phase 3 ATTR-ACT Study
www.nasdaq.com - September 18 at 10:47 AM
Watson Health Still the Key Driver for IBM’s AI BusinessWatson Health Still the Key Driver for IBM’s AI Business
finance.yahoo.com - September 18 at 10:47 AM
Pfizer Invites Public to View and Listen to Webcast of October 30 Conference Call with AnalystsPfizer Invites Public to View and Listen to Webcast of October 30 Conference Call with Analysts
finance.yahoo.com - September 18 at 10:47 AM
A Review of Pharma Stocks’ EPS Growth RatesA Review of Pharma Stocks’ EPS Growth Rates
finance.yahoo.com - September 18 at 10:47 AM
How Pharmaceutical ETFs Have Performed in 2018How Pharmaceutical ETFs Have Performed in 2018
finance.yahoo.com - September 17 at 3:35 PM
A Look at the Market Caps of the Pharma Stocks under ReviewA Look at the Market Caps of the Pharma Stocks under Review
finance.yahoo.com - September 17 at 3:35 PM
This cancer-fighting biotech sped from startup to IPO filing in 10 monthsThis cancer-fighting biotech sped from startup to IPO filing in 10 months
finance.yahoo.com - September 17 at 10:30 AM
Pfizer Inc. (PFE) Receives Average Recommendation of "Hold" from AnalystsPfizer Inc. (PFE) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 17 at 4:52 AM
Pfizers JAK inhibitors show positive effect in mid-stage alopecia areata studyPfizer's JAK inhibitors show positive effect in mid-stage alopecia areata study
seekingalpha.com - September 16 at 10:11 AM
Pfizer (PFE) Outpaces Stock Market Gains: What You Should KnowPfizer (PFE) Outpaces Stock Market Gains: What You Should Know
finance.yahoo.com - September 15 at 10:17 AM
Pfizer Reports Positive Phase 2 Data Of JAK Inhibitors In Alopecia AreataPfizer Reports Positive Phase 2 Data Of JAK Inhibitors In Alopecia Areata
www.nasdaq.com - September 15 at 10:17 AM
How Spark Therapeutics Is Positioned in 2018How Spark Therapeutics Is Positioned in 2018
finance.yahoo.com - September 14 at 3:36 PM
Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in FocusPharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
finance.yahoo.com - September 14 at 3:36 PM
Pfizer (PFE) Given a $45.00 Price Target by Morgan Stanley AnalystsPfizer (PFE) Given a $45.00 Price Target by Morgan Stanley Analysts
www.americanbankingnews.com - September 13 at 10:33 AM
Pfizer (PFE) PT Set at $45.00 by Cantor FitzgeraldPfizer (PFE) PT Set at $45.00 by Cantor Fitzgerald
www.americanbankingnews.com - September 13 at 10:32 AM
JNJ Stock Up 7% in the Past Month: What Drove the Bulls?JNJ Stock Up 7% in the Past Month: What Drove the Bulls?
finance.yahoo.com - September 13 at 10:27 AM
Your Cancer Highlight: Pfizer Gets Ready For An Imminent Lung Cancer ApprovalYour Cancer Highlight: Pfizer Gets Ready For An Imminent Lung Cancer Approval
seekingalpha.com - September 12 at 3:34 PM
Pfizers Drug Combo Betters Survival in Kidney Cancer StudyPfizer's Drug Combo Betters Survival in Kidney Cancer Study
www.zacks.com - September 12 at 10:02 AM
Pfizer to suspend operations at NC injectables plant ahead of Hurricane FlorencePfizer to suspend operations at NC injectables plant ahead of Hurricane Florence
seekingalpha.com - September 11 at 3:34 PM
Merck, Pfizer Report Positive Top-line Results From Phase III JAVELIN 101 StudyMerck, Pfizer Report Positive Top-line Results From Phase III JAVELIN 101 Study
www.nasdaq.com - September 11 at 10:54 AM
A Look At Pfizers Business And OutlookA Look At Pfizer's Business And Outlook
www.forbes.com - September 10 at 3:13 PM
Johnson & Johnson Vs. Pfizer: You Cant Go Wrong With Either StockJohnson & Johnson Vs. Pfizer: You Can't Go Wrong With Either Stock
seekingalpha.com - September 10 at 11:06 AM
The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & JohnsonThe Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson
finance.yahoo.com - September 10 at 11:06 AM
Pfizer (PFE) PT Set at $42.00 by JPMorgan Chase & Co.Pfizer (PFE) PT Set at $42.00 by JPMorgan Chase & Co.
www.americanbankingnews.com - September 10 at 10:44 AM
Pfizer (PFE) Price Target Raised to $47.00Pfizer (PFE) Price Target Raised to $47.00
www.americanbankingnews.com - September 7 at 10:27 AM
Your first trade for Friday, Sept 7Your first trade for Friday, Sept 7
finance.yahoo.com - September 7 at 10:19 AM
Pfizer Inc. (PFE) Expected to Announce Quarterly Sales of $13.51 BillionPfizer Inc. (PFE) Expected to Announce Quarterly Sales of $13.51 Billion
www.americanbankingnews.com - September 7 at 3:56 AM
Pfizer’s PF-06651600 Receives a Breakthrough Therapy DesignationPfizer’s PF-06651600 Receives a Breakthrough Therapy Designation
finance.yahoo.com - September 6 at 3:34 PM
Pfizer (PFE) Given a $40.00 Price Target by Credit Suisse Group AnalystsPfizer (PFE) Given a $40.00 Price Target by Credit Suisse Group Analysts
www.americanbankingnews.com - September 6 at 1:29 PM
Morgan Stanley Analysts Give Pfizer (PFE) a $45.00 Price TargetMorgan Stanley Analysts Give Pfizer (PFE) a $45.00 Price Target
www.americanbankingnews.com - September 6 at 12:33 PM
Pfizers Skin Disease Drug Gets Breakthrough Therapy StatusPfizer's Skin Disease Drug Gets Breakthrough Therapy Status
www.zacks.com - September 6 at 10:48 AM
Large Cap Pharma Stocks Staging a Comeback in Second HalfLarge Cap Pharma Stocks Staging a Comeback in Second Half
finance.yahoo.com - September 6 at 10:48 AM
Top Analyst Reports for Pfizer, Salesforce & ADPTop Analyst Reports for Pfizer, Salesforce & ADP
www.zacks.com - September 5 at 3:37 PM
$0.75 Earnings Per Share Expected for Pfizer Inc. (PFE) This Quarter$0.75 Earnings Per Share Expected for Pfizer Inc. (PFE) This Quarter
www.americanbankingnews.com - September 5 at 12:19 PM
Pfizer Gets Breakthrough Therapy Designation From FDA For PF-06651600Pfizer Gets Breakthrough Therapy Designation From FDA For PF-06651600
www.nasdaq.com - September 5 at 10:40 AM
Pfizer receives Breakthrough Therapy designation for PF-06651600 for the treatment of patients with alopecia areataPfizer receives Breakthrough Therapy designation for PF-06651600 for the treatment of patients with alopecia areata
seekingalpha.com - September 5 at 10:40 AM
Pfizer (PFE) Gains FDA Breakthrough Therapy Designation for PF-06651600Pfizer (PFE) Gains FDA Breakthrough Therapy Designation for PF-06651600
www.streetinsider.com - September 5 at 10:40 AM
This page was last updated on 9/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel